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BACKGROUND: Poly adenosine diphosphate (ADP)-ribose polymerase (PARP) is essential in cellular processing of DNA damage via the
base excision repair pathway (BER). The PARP inhibition can be directly cytotoxic to tumour cells and augments the anti-tumour effects
of DNA-damaging agents. This study evaluated the optimally tolerated dose of olaparib (4-(3–4-fluorophenyl) methyl-1(2H)-one;
AZD2281, KU0059436), a potent PARP inhibitor, with dacarbazine and assessed safety, toxicity, clinical pharmacokinetics and efficacy
of combination treatment.
PATIENTS AND METHODS: Patients with advanced cancer received olaparib (20–200mg PO) on days 1–7 with dacarbazine
(600–800mgm
 2 IV) on day 1 (cycle 2, day 2) of a 21-day cycle. An expansion cohort of chemonaive melanoma patients was treated
at an optimally tolerated dose. The BER enzyme, methylpurine-DNA glycosylase and its substrate 7-methylguanine were quantified in
peripheral blood mononuclear cells.
RESULTS: The optimal combination to proceed to phase II was defined as 100mgbd olaparib with 600mgm
 2 dacarbazine. Dose-
limiting toxicities were neutropaenia and thrombocytopaenia. There were two partial responses, both in patients with melanoma.
CONCLUSION: This study defined a tolerable dose of olaparib in combination with dacarbazine, but there were no responses in
chemonaive melanoma patients, demonstrating no clinical advantage over single-agent dacarbazine at these doses.
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One of the primary roles of poly adenosine diphosphate (ADP)-
ribose polymerase-1 (PARP-1) is to detect DNA strand breaks
that occur following DNA damage. Activation of PARP-1 in this
setting results in DNA repair via the base excision repair pathway
(BER) (Virag and Szabo, 2002). The PARP-1 activity is frequently
increased in tumour cells, with evidence that inhibition of PARP
can be cytotoxic (Chalmers, 2009). The PARP inhibition leads
to accumulation of DNA single-strand breaks resulting in DNA
double-strand breaks at replication forks. The PARP-1 inhibition
augments the anti-tumour effects of many DNA-damaging
cytotoxic agents or radiation (Chalmers, 2009).
Olaparib (4-(3–4-fluorophenyl) methyl-1(2H)-one; AZD2281)
is a potent, orally active, PARP inhibitor (Menear et al, 2008).
Olaparib combined with the methylating agent temozolomide,
a pro-drug of 3-methyl-(triazen-1-yl-4-carboxamide (MTIC),
enhances cytotoxicity in tumour cell lines and xenografts
(Menear et al, 2008). Dacarbazine, dimethyltriazenoimidazole
carboxamide (DTIC) which is also activated to form MTIC, was
selected for clinical investigation in combination with olaparib to
explore the combination’s activity in melanoma.
DNA adducts, such as 3-methyladenine (3meA) and N7-methyl-
guanine (7-meG), that are produced in DNA following exposure to
dacarbazine are processed by the BER pathway (Fromme et al,
2004). A damage-specific DNA glycosylase removes the alkylated
DNA base, resulting in the generation of apurinic sites that are
cleaved by the abundant endonuclease, APE, and the resulting
single-strand breaks are repaired by the coordinated intervention
of PARP, DNA polymerase b, X-ray repair cross-complementing-1
and ligases I and III (Dantzer et al, 1999). The PARP senses and is
activated by the DNA single strand breaks and catalyses poly ADP
ribosylation and consequent activation of the various proteins
involved in the BER pathway.
The aim of combining dacarbazine with olaparib was to disrupt
BER function, and thus elicit an accumulation of strand breaks and
ultimately increased cytotoxicity. Given the requirement of single-
strand break formation in this process, PARP inhibition may
have a greater impact in cells with a greater ability to remove
the damaged bases, that is, with higher N-methylpurine-DNA
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sglycosylase (MPG) activity. This activity may itself be upregulated
by combination treatment with a PARP inhibitor and an alkylating
agent, and this may have consequences for cell death, as 3meA is a
toxic DNA lesion (Tentori et al, 1999, 2001).
The rationale for this study (KU36-73, NCT00516802) was
that intermittent dosing of olaparib, given in combination with
dacarbazine, would sufficiently inhibit the PARP-1 repair of
methylated DNA to produce an enhanced clinical effect. Primary
objectives were to determine the safety, tolerability and dose-
limiting toxicity (DLT) of a combination of oral olaparib and
intravenous dacarbazine in patients with advanced solid tumours.
Secondary objectives were to determine the pharmacokinetic
profile of olaparib in combination with dacarbazine, to investigate
the pharmacokinetic–pharmacodynamic profile of the combina-
tion in surrogate tissues and to enable a preliminary assessment
of their anti-tumour activity. Thus both inter- and intraindividual
variations in MPG activity during the course of the KU-DTIC
treatment cycle were measured. Levels of 7-meG in DNA were
quantified before treatment and following DTIC as both an
indicator of the level of alkylation damage generated and an
indicator of the amounts lost through repair or cell turnover,
respectively.
PATIENTS AND METHODS
The study was conducted in accordance with the Principles of the
International Conference on Harmonization of Good Clinical
Practice guidelines and the Declaration of Helsinki. The protocol
was approved by an independent ethics committee, according
to UK and local requirements. All patients enroled in the study
gave informed written consent (KU36-73, NCT00516802).
Individuals aged X18 years with a life expectancy of at least
3 months were eligible for the study. The ECOG performance
status of 2 or better, adequate hepatic, renal and bone marrow
function, and platelet count were required. For the initial
dose-escalation cohorts, patients had to have a histologically or
cytologically confirmed malignant solid tumour refractory to
standard therapy. At a dacarbazine dose of 800mgm
 2 in the
escalation phase and in the dose-expansion phase, only patients
with unresectable stage III/IV cutaneous or unknown primary
melanoma and no previous systemic cytotoxic chemotherapy were
allowed to participate.
Treatment
Olaparib (AstraZeneca, Macclesfield, UK) was administered orally
as capsules twice daily on days 1–7 of each 21-day treatment cycle.
In cycle 2, olaparib was administered on days 2–8 to permit the
pharmacokinetics of dacarbazine given alone to be determined.
Dacarbazine (Bayer, Bedford, UK) was administered by intrave-
nous infusion over 60min on day 1 of each cycle, 3h after olaparib
administration (except in cycle 2).
Study design
The starting dose was olaparib 10mgbd with 600mgm
 2
dacarbazine (10: 600: combination doses will be abbreviated in
this way for the remainder of the manuscript). The dose for
successive cohorts was modified according to the scheme
presented in Figure 1 taking into account the toxicities experienced
by preceding patient cohorts.
The DLT was defined as any of the following: grade 4
haematological toxicity lasting X5 days; grade 3 or 4 febrile
neutropaenia; and grade 3 or 4 non-haematological toxicity.
However, grade 3 or greater non-haematological toxicities were
not classified as DLTs, if the nature and severity of the toxicity was
attributable to DTIC alone. If one out of three patients at a dose
level developed DLT, up to three additional patients were treated
at that dose level. If one out of the additional patients developed
DLT, dose escalation ceased and a preceding dose level or an
intermediate dose level was tested. This lower dose was defined
as the maximum tolerated dose for that dose of dacarbazine,
unless X2 out of 6 patients developed DLT.
The dose-expansion phase involved 10 patients treated at the
selected olaparib and dacarbazine doses, with the option to move
to a randomised expansion phase, if a 20% overall response rate
was observed.
Toxicity and response evaluation
Safety assessments included physical examination, chemistry,
haematology and urinalysis. Toxicities were evaluated at least weekly
during the study period and were graded according to the National
Cancer Institute Common Toxicity Criteria version 3 (Tsuchida
and Therasse, 2001). Efficacy was assessed every other cycle.
Olaparib
40 mg bd
DTIC 800 mgm–2
Dose escalation phase part II:
patients with advanced
melanoma who have not
previously received systemic
chemotherapy.
Dose escalation phase part I:
patients with solid tumors
refractory to standard therapy or
for whom no suitable effective
standard therapy exists.
Confirmation phase:
10 patients with advanced
melanoma who have not
previously received systemic
chemotherapy.
Olaparib
20 mg bd
DTIC 800 mgm–2
Olaparib
10 mg bd
DTIC
600 mgm–2
Olaparib
20 mg bd
DTIC
600 mgm–2
Olaparib
40 mg bd
DTIC
600 mgm–2
Olaparib
100 mg bd
DTIC
600 mgm–2
Olaparib
20 mg bd
DTIC
600 mgm–2
Olaparib
100 mg bd
DTIC
600 mgm–2
Figure 1 Chronological flow chart of implemented study design cohorts.
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sPharmacodynamics
The MPG activity and levels of 7-meG in DNA were determined in
peripheral blood mononuclear cells before and following treatment
with dacarbazine. Samples were obtained on days 1 and 8 of the
treatment cycle, and analysed according to previously published
methods. The MPG activity in the cell extract was quantified by
an oligonucleotide cleavage assay. The amounts of 7-meG in
peripheral blood DNA were quantified according to an immuno-
blot method (Harrison et al, 2001).
N-methylpurine-DNA glycosylase activity
Whole blood (1ml) was thawed, centrifuged at 3700g for 10min
and the supernatant discarded. The cell pellet was resuspended
in buffer, and extracts prepared by sonication as described by
Harrison et al (2001). The MPG activity in the cell extract was
quantified by an oligonucleotide cleavage assay. Briefly, an
oligonucleotide containing ethenoadenine (a substrate for MPG)
close to the 50-end was labelled with
32P gATP, annealed to its
50-biotinylated complement and immobilised on a streptavidin-
coated 96-well plate. Incrementally increasing amounts of cell
extract based on DNA content as quantified by picogreen-based
assay (Invitrogen Ltd., Paisley, UK) were incubated with the
substrate oligonucleotide for 3h at 371C. The
32P-labelled 5-mer
released into the supernatant as a result of removal of etheno-
adenine by MPG, and the subsequent action of APE were
quantified on a TOP COUNT machine (Perkin Elmer LAS,
Beaconsfield, UK). Specific activity was calculated as femtomoles
(Fmoles) ethenoadenine removed per mg of extract DNA per hour.
The lower limit of quantitation (LLOQ) was defined as 2.3Fmoles
ethenoadenine removed per mg DNA per hour.
N7-methylguanine in DNA
The amounts of 7-meG in peripheral blood DNA were quantified in
pre- and post-DTIC treatment (day 1 at 5h and day 8) samples
according to the immunoblot method previously described
(Menear et al, 2008). The chemiluminescence signal was generated
by incubation with ECL-Advance (Amersham, Chalfont St Giles,
UK), detected with the Chemi Genius Bio Imaging System
(Syngene, Cambridge, UK) and quantified using Genetools soft-
ware (Syngene). The LLOQ was defined as 0.3Fmoles 7-meG
per mg DNA.
Pharmacokinetics
Venous blood was drawn for determination of pharmacokinetic
profiles for olaparib and dacarbazine when dosed alone and in
combination. Blood samples were collected before the patients
started taking olaparib and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 9–10h
after taking the drug on day 1 of cycle 1. Blood samples were also
collected before the start of the dacarbazine infusion and 0.5, 1, 2
and 5–6h after the end of infusion to quantify plasma levels of
dacarbazine on day 1 of cycles 1 and 2. Plasma dacarbazine and
olaparib concentrations were determined by high-performance
liquid chromatography with tandem mass spectrometric detection.
RESULTS
A total of 40 patients were enroled in the study at three centres,
and their characteristics are summarised in Tables 1 and 2. All
40 patients were evaluable for toxicity and for tumour response.
Dose escalation and extent of exposure
A total of 153 cycles (median 2.5 cycles per patient) of olaparib and
dacarbazine were administered in the study. There were no dose
reductions of olaparib, although six patients were non-compliant
and missed one dose of their olaparib treatment each. Four
patients required dacarbazine dose reductions of 200mgm
 2 and
in one patient, a second dose reduction was needed because of
haematological toxicity.
During the dose-escalation phase of the trial, three cohorts of
patients were successfully treated without major potentiation of
toxicity or serious side effects. When patients were treated with
40: 800 in part II, a higher incidence of bone marrow toxicity,
particularly neutropaenia, was noted compared with rates reported
for single-agent DTIC. Although the toxicities were not dose
limiting per protocol, it was apparent that the dose combination of
40: 800 could not be sustained over several cycles. Therefore, the
protocol was amended to allow a dose combination of 600mgm
 2
DTIC in combination with increasing olaparib doses from 40 to
200mgbd to be explored.
Three patients in the dose-escalation phase experienced a
DLT during the first treatment cycle. One occurred in
cohort 4 (40: 800) and two in cohort 6 (200: 600). The highest
combination doses that were deliverable were 100: 600 and 20: 800.
Maximal PARP inhibition was observed at doses above 60mgbd
in single-agent trials so the 100: 600 dose combination
was chosen for the dose-expansion component of the study
(Fong et al, 2009).
Safety
Adverse events were as anticipated for dacarbazine (Table 3). Most
frequent toxicities were neutropaenia and anaemia, although
nausea, fatigue, anorexia, diarrhoea and thrombocytopaenia
were common. As anticipated, the incidence of neutropaenia was
higher than that observed with single-agent dacarbazine, affecting
10 patients and in 9 of these, the severity was Xgrade 3. Two
patients died within 30 days of receiving study drug. Neither death
was considered to be related to the combination treatment: one
because of myocardial ischaemia and the other to pneumonia in
the setting of progressive disease.
Dose-limiting toxicities
One patient treated with 40: 800 experienced grade 3 hypopho-
sphataemia and grade 3 leucopoenia. Cycle 2 was delayed because
of thrombocytopaenia, which peaked at grade 3 and did not
recover until day 49. The patient was taken off study because
of these toxicities. Two patients treated with 200: 600 experienced
Table 1 Patient demographics
Number of patients 40
Mean age, years (range) 53.3 (19–75)
Gender (male/female) 28/12
Performance status (0/1/2) 23/15/2
Tumour type (n)
Melanoma 33
Colorectal 2
Transitional cell carcinoma bladder 1
Squamous cell carcinoma vulva 1
Haemangioblastoma 1
Merkel cell carcinoma 1
Adenocarcinoma lung 1
Previous chemotherapy regimens (n)
02 1
17
27
X35
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considered to be dose limiting, although the duration
of neutropaenia could not be confirmed. These two dose levels
were not chosen for further evaluation because of the toxicities
observed in these cohorts, in particular the occurrence of
neutropaenia in one-third of patients in each of the cohorts with
insufficient recovery before the date of the next planned
dacarbazine infusion.
Efficacy
All patients were evaluable for efficacy. Two partial responses were
documented, and eight patients had stable disease where follow-up
measurements must have met the stable disease criteria at least
once after trial entry at a minimum interval of 12 weeks. The other
30 patients progressed on treatment (Table 4). Both partial
responses were seen in patients with previously treated melanoma:
Table 2 Disposition of patients across different cohorts
Baseline characteristics
10/600
(n¼3)
20/600
(n¼4)
20/800
(n¼4)
40/600
(n¼4)
40/800
(n¼6)
100/600
(n¼13)
200/600
(n¼6)
Total
(n¼40)
Refractory solid tumour, n (%) 3 (100) 4 (100) 0 4 (100) 0 3 (23.1) 6 (100) 20 (50)
First-line melanoma, n (%) 0 0 4 (100) 0 6 (100) 10 (76.9) 0 20 (50)
Malignant melanoma, NOS, n (%) 3 (100) 1 (25) 4 (100) 1 (25) 6 (100) 12 (92.3) 3 (50) 30 (75)
Other, n (%) 0 3 (75) 0 3 (75) 0 1 (7.7) 3 (50) 10 (25)
Abbreviation: NOS¼not otherwise specified.
Table 3 Summary of number (%) of patients with adverse events of grade 3 or higher, occurring in at least 5% of patients
Initial dose level (olaparib mgbd per DTIC mgm
 2)
Number of patients with AE (%)
10/600
(n¼3)
20/600
(n¼4)
20/800
(n¼4)
40/600
(n¼4)
40/800
(n¼6)
100/600
(n¼13)
200/600
(n¼6)
Total overall
(n¼40)
Patients with any grade 3 or higher
adverse events
2 (66.7) 4 (100) 1 (25.0) 2 (50.0) 5 (83.3) 9 (69.2) 6 (100) 29 (72.5)
Blood and lymphatic system
Anaemia 0 1 (25.0) 0 0 0 0 1 (16.7) 2 (5.0)
Leucopoenia 0 1 (25.0) 0 0 1 (16.7) 1 (7.7) 2 (33.3) 5 (12.5)
Lymphopaenia 0 1 (25.0) 0 0 1 (16.7) 2 (15.4) 2 (33.3) 6 (15.0)
Neutropaenia 0 1 (25.0) 0 0 3 (50.0) 3 (23.1) 2 (33.3) 9 (22.5)
Thrombocytopaenia 0000 1 (16.7) 0 2 (33.3) 3 (7.5)
Gastrointestinal
Abdominal pain upper 0000 1 (16.7) 1 (7.7) 0 2 (5.0)
Metabolism and nutrition
Hyperglycaemia 0 0 0 1 (25.0) 0 1 (7.7) 0 2 (5.0)
Hyponatraemia 1 (33.3) 1 (25.0) 0 0 0 0 0 2 (5.0)
Hypophosphataemia 1 (33.3) 1 (25.0) 0 0 1 (16.7) 1 (7.7) 0 4 (10.0)
Musculoskeletal and connective tissue
Arthralgia 0 0 0 1 (25.0) 1 (16.7) 0 0 2 (5.0)
Back pain 0000 1 (16.7) 1 (7.7) 0 2 (5.0)
Nervous system
Lethargy 0 0 1 (25.0) 0 0 1 (7.7) 0 2 (5.0)
Abbreviations: AE¼adverse events; CTCAE¼Comman Terminology Criteria for Adverse Events, CTCAE grade 3¼severe; 4¼life threatening or disabling;
DTIC¼dimethyltriazenoimidazole carboxamide.
Table 4 Overall best response summary (RECIST): intent-to-treat population
Initial dose level (olaparib mgbd per DTIC mgm
 2)
Overall best response,
n (%)
10/600
(n¼3)
20/600
(n¼4)
20/800
(n¼4)
40/600
(n¼4)
40/800
(n¼6)
100/600
(n¼13)
200/600
(n¼6)
Total
(n¼40)
Partial response 0 0 0 1 (25.0) 0 0 1 (16.7) 2 (5.0)
Progressive disease 3 (100) 3 (75.0) 4 (100) 3 (75.0) 5 (80.0) 9 (69.2) 3 (50.0) 30 (75.0)
Stable disease 0 1 (25) 0 0 1 (20.0) 4 (30.8) 2 (33.3) 8 (20.0)
Abbreviation: RECIST¼response evaluation criteria in solid tumors.
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and the other where they had received one previous regimen.
The median time to disease progression was 82 days (95% confi-
dence interval (CI): 38–108 days) in the dose-escalation phase in
refractory solid tumour patients and 42 days (95% CI: 36–84 days)
for chemotherapy-naive melanoma patients. The median time to
disease progression overall was 43 days (95% CI: 36–108 days).
Pharmacokinetics
A total of 29 patients provided evaluable pharmacokinetic data for
olaparib with or without dacarbazine. The co-administration of
dacarbazine appeared to have had little or no effect on exposure to
olaparib, with respect to peak concentration (Cmax) or area under
the concentration–time curve. Similarly, in 17 evaluable patients,
there was no discernable impact of olaparib on dacarbazine
pharmacokinetics.
Pharmacodynamics
Blood samples collected from 24 patients were available for analysis.
For individual patients, MPG activities did not vary significantly or
consistently over the course of the sampling (Figure 2A), indicating
that MPG activity was not substantially affected by the doses and
schedules of olaparib and dacarbazine used in this study, or sampling
times. Mean MPG activity, basedo na l lt i m e sp o i n t sm e a s u r e d ,
showed marked interpatient variation, with values ranging from 3.3
to 16.2Fmol per mgD N Ap e rh o u r( m e a n ±s.d. 8.7±6.0; Figure 2B).
Levels of 7-meG before treatment were less than the LLOQ for
14 out of the 20 patients analysed, with very low levels in the other
6 individuals (range 0.3–1.6Fmol per mg DNA). Mean 7-meG
levels rose significantly (Po0.01) on day 1, 5h after dacarbazine
administration (50.5±8.2Fmol per mg DNA, n¼24), and
remained above baseline at day 8 (14.6±5.4Fmol per mg DNA,
n¼5). This is consistent with previous observations made
following temozolomide treatment (Watson et al, 2009) that levels
reduce over time, most likely because of cell turnover and/or
removal of 7-meG by MPG. Mean 7-meG levels after treatment
were higher in patients treated with 800mgm
 2 dacarbazine
(55.3±8.1Fmol per mg DNA) than those treated with 600mgm
 2
(47.4±8.3Fmol per mg DNA) (Po0.05). There was no correlation
between MPG activity and 7-meG levels after dacarbazine
administration in individual patients (Figure 2C). Unfortunately,
no data were available from the two patients who had partial
responses on treatment.
DISCUSSION
Treatment options for patients with metastatic melanoma are
limited, with existing therapies only producing low rates of
objective radiological responses and short periods of clinical
benefit. Dacarbazine remains the standard of care and is the
benchmark against which other therapies are compared.
This is the first study evaluating the optimally tolerated dose
of olaparib, a potent PARP inhibitor, in combination with
dacarbazine in patients with either advanced solid tumours or
chemotherapy-naive melanomas. Adverse event rates were similar
to those previously reported for dacarbazine alone at doses
from 800 to 1000mgm
 2, with the exception of neutropaenia.
Myelosuppression occurs in about 25% of patients treated with
dacarbazine, but grade 3 or 4 events are seen in only 1–2% (Bajetta
et al, 1994; Middleton et al, 2000). As expected from other studies
with PARP inhibitors in combination with temozolomide and pre-
clinical studies with olaparib significant myelotoxicity, especially
neutropaenia was more frequent and defined the dose of the two
drugs for combined use. Grade 3 or 4 neutropaenia affected nine
patients (22.5%) in this study, and appeared more frequent with
higher doses of dacarbazine or olaparib. The increased neutropae-
nia, although readily managed, led to an increase in delays in the
administration of the second cycle of therapy and reductions in the
dose of dacarbazine in the highest dose cohorts.
The 100mgbd olaparib and 600mgm
 2 dacarbazine dose
combination was chosen for the dose confirmation component
of the study. Monotherapy olaparib studies had indicated that
doses of 100mgbd or above were clinically efficacious and
inhibited PARP-1 (Fong et al, 2009), so this combination was
preferred over one with a higher dacarbazine dose and 20mgbd
olaparib. Although dose modifications were required for some
patients, this dose was generally well tolerated in chemonaive
melanoma patients, confirming its suitability for use outside of a
clinical trial setting. Experience of myelosupression with PARP
inhibitors and methylating agents to date has been variable. Use of
AG-14699 required a reduction in the dose of temozolomide given
concurrently, as was the case in the current study. However, full-
dose temozolomide can be administered with a PARP-inhibitory
dose of veliparib (ABT-888). The basis for this difference in the
enhancement of myelotoxicity is not clear, as all the drugs are
potent PARP-1 inhibitors.
The dose confirmation cohort was also designed to give a
preliminary assessment of the efficacy of this dose combination,
before potentially expanding recruitment to compare combi-
nation therapy with dacarbazine alone. The minimum efficacy
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srequirement to move to the randomised phase of the trial was
an objective response rate of 20% or greater after four cycles of
treatment. As there were no further responses in the 10 melanoma
patients treated first line with the combination, this requirement
was not met and the expansion phase of the study was not opened.
Progression-free survival was similar to that obtained with
dacarbazine and temozolomide in previous clinical trials (Eigentler
et al, 2003; Quirt et al, 2007).Given the limited numbers of
chemotherapy-naive melanoma patients in this study, the possi-
bility of a small benefit for the addition of the PARP inhibitor in
this group of patients cannot be excluded.
The MPG activity was detectable in all samples analysed, showed
considerable interpatient variation (Figure 2A) but was not signi-
ficantly affected by administration of either olaparib or dacarba-
zine or sampling time (Figure 2B). It was anticipated that MPG
activity might influence 7-meG levels, but this proved not to be
the case (Figure 2C). As dacarbazine requires metabolic activation
for conversion to a methylating species, interpatient differences in
metabolism will influence initial methylation levels, potentially
confounding any correlation between MPG activity and 7-meG.
However, mean 7-meG levels measured 5h after dacarbazine
administration were remarkably consistent, so this is unlikely to
explain the lack of correlation. Thus, in peripheral blood mono-
nuclear cells, the availability of functional MPG is not the principal
determining factor in the loss of 7-meG. Although there are no
reports of other repair processes acting on this lesion, it is possible
that factors such as MPG recruitment to damage site, cofactors and
coupling to transcription-coupled or global genome repair
processes, may modulate 7-meG removal.
A phase I study of AG014699 with temozolomide in patients
with metastatic melanoma was the first clinical trial of a PARP inhi-
bitor in combination with chemotherapy (Plummer et al, 2008).
The combination was well tolerated, with some evidence
of activity. However, in a phase II study of the combination, the
haematological toxicity of temozolomide was exacerbated with one
toxic death, three neutropaenic hospitalisations and dose reduc-
tions of temozolomide in a significant proportion of patients,
highlighting the differences that can occur, as regimens identified
in select populations in phase I trials are applied more widely. The
level of PARP inhibitor activity has not been reported (Plummer
et al, 2006). Other PARP inhibitors have been tested in melanoma
in combination with a variety of cytotoxic or targeted agents.
By far the largest study of this approach is the recently completed
randomised phase 2 trial of ABT-888 and temozolomide. This trial
of over 300 patients will provide the clearest insight into the
potential for PARP inhibition in melanoma when its results become
known late in 2010.
In conclusion, this phase I study identified clinically tolerable doses
of olaparib and dacarbazine for use in combination therapy in
patients with metastatic melanoma. However, no responses were seen
in 10 chemotherapy-naive melanoma patients treated at the optimal
combination doses identified. Despite the small size of this group, it is
unlikely that this combination, at these doses, will provide a clinically
important advantage over single-agent dacarbazine as first-line
treatment in patients with advanced melanoma.
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